Program
adagrasib
Also written as “Adagrasib”, “MRTX849” and “Eltrombopag + adagrasib”.
Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Biliary Tract Neoplasms, led by 2 companies.
Drug pageAdagrasib: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 157 open or running | phase 3since Oct 28, 2020 | Dec 18, 2018 | Feb 16, 2028phase 2 · NCT07415031 |
| Zai Lab | 10 open or running | phase 1since Jan 13, 2022 | Jan 13, 2022 | none ahead |
Also a collaborator on its studies: Aadi Bioscience, Novartis and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zai Lab only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named adagrasibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, MRTX849
- Jan 13, 2022First study: phase 1 study in Neoplasm MetastasisFirst studyNCT05263986 · 22 enrolled · China
TargetBeta
“An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
The one study Zai Lab leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05263986Neoplasm Metastasis · China | 1 | UNKNOWN | Oct 31, 2023 | 22 |
How it is read
Names in the registry
- “Adagrasib”, 12 entries
- “MRTX849”, 7 entries
- “Eltrombopag + adagrasib”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Colorectal Neoplasms, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.